FunPep Company Limited
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥1M | ¥1M | ¥6M | ¥0M |
| Gross Profit | -¥911M | -¥680M | -¥536M | -¥1,296M |
| Operating Income | -¥1,169M | -¥994M | -¥902M | -¥1,649M |
| Pretax Income | -¥1,169M | -¥994M | -¥902M | -¥1,649M |
| Net Income | -¥1,173M | -¥933M | -¥889M | -¥1,912M |
| EPS | -¥61.04 | -¥39.63 | -¥31.98 | - |
| Operating Margin | -109,565.98% | -187,567.36% | -14,717.76% | -525,053.50% |
| Balance Sheet | ||||
| Total Assets | ¥2,993M | ¥2,491M | ¥3,111M | ¥1,981M |
| Total Equity | ¥2,695M | ¥2,302M | ¥2,547M | ¥1,464M |
| Total Liabilities | ¥298M | ¥189M | ¥563M | ¥517M |
| Cash | ¥2,245M | ¥1,793M | ¥2,346M | ¥1,768M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 90.04% | 92.40% | 81.90% | 73.91% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | -¥1,053M | -¥989M | -¥537M | -¥1,388M |
| Investing CF | -¥19M | -¥1M | -¥31M | -¥1M |
| Financing CF | ¥245M | ¥538M | ¥1,120M | ¥811M |
| Free CF | -¥1,066M | -¥990M | -¥538M | -¥1,388M |
| Efficiency | ||||
| ROE | -43.51% | -40.55% | -34.90% | -130.56% |
| ROA | -39.18% | -37.47% | -28.58% | -96.50% |
Latest IR Information
-
【FanPep】Clinical Trial Milestone for Antibody-Inducing Peptide | July 2026
Announced preliminary results of Phase I clinical trial of the antibody-inducing peptide FPP004X. Good safety profile, confirmed increase in anti-IgE antibody levels. Future development plans to be discussed.
Read more -
Notice Regarding Recognition of Non-Operating Income (Grant Revenue)
Read more -
Notice of Completion of Exercise and Monthly Exercise Status for the 13th Redeemable Subscription Rights (with Exercise Price Revision Clause)
All exercises of the stock-based compensation rights (13th issue, with exercise price adjustment clause) have been completed as of June 10. The number of shares issued for the target month is 1,739,000 shares, the exercise ratio is 17.84%, unexercised rights...
Read more -
Notice of Partnership Agreement for the Development of Transdermal Absorption Formulations of Antibody-Induced Peptides
FanPep entered into a joint research agreement with artience Co., Ltd. and Toyo Chemical Co., Ltd. for the development of transdermal delivery formulations of antibody-inducing peptides. FanPep will conduct efficacy and safety evaluations in animal studies, bearing the costs. There...
Read more -
Notice Regarding the Exercise of Stock Acquisition Rights in Large Volume - 13th Share Option
We report the status of the stock acquisition rights exercised from June 1 to 4, 2026. Approximately 12,193 shares were exercised at an exercise price of 55 yen. This information is significant as it impacts future share issuance activities.
Read more
Latest News (5 items)
Company Information
About
FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices in Japan and internationally. The company develops SR-0379, a functional peptide which is in Phase III clinical trial for the treatment of skin ulcer; FPP003, an antibody-inducing peptide which is in Phase II clinical trial for the treatment of psoriasis and ankylosing spondylitis; FPP004X, an antibody-inducing peptide which is in Phase I clinical trial for the treatment of pollinosis; and FPP005, an antibody-inducing peptide which is in pre-clinical trial stage for the treatment of psoriasis. It is also involved in the development of Curepeptin, an antimicrobial peptide that disrupts bacterial cell membranes. The company was incorporated in 2013 and is headquartered in Ibaraki, Japan.
